All Photos(1)




Anti-Phosphacan Antibody, clone 122.2

ascites fluid, clone 122.2, Chemicon®

Sign Into View Organizational & Contract Pricing

Receptor Tyrosine Phosphatase beta

biological source


Quality Level

antibody form

ascites fluid

antibody product type

primary antibodies


122.2, monoclonal

species reactivity





immunocytochemistry: suitable
immunohistochemistry: suitable
western blot: suitable



UniProt accession no.

shipped in

dry ice

target post-translational modification


Gene Information

human ... PTPRZ1(5803)

General description

Phosphacan is a soluble nervous tissue-specific proteoglycan that is thought to regulate axonal outgrowth. It is synthesized by glia and binds to neurons and to the neural cell adhesion molecules tenascin, N-CAM or NG-CAM but not to laminin and fibronectin. Phosphacan acts as a potent inhibitor of cell adhesion and neurite outgrowth.


Phosphacan (Receptor Tyrosine Phosphatase Beta). Recognizes the core protein.


Anti-Phosphacan Antibody, clone 122.2 detects level of Phosphacan & has been published & validated for use in WB, IC, IH.
Research Category
Research Sub Category
Growth Cones & Axon Guidance
Western blot. Recognizes bands at 250, 190, and 180 kDa on western blots of embryonic rat brain extracts.

Immunocytochemistry: 1:10

Immunohistochemistry on 4% paraformaldehyde fixed tissue: 1:1,000


Optimal working dilutions must be determined by the end user.

Physical form

Ascites fluid. Liquid. Contains no preservative.

Storage and Stability

Maintain at -20°C in undiluted aliquots up to 6 months. Avoid repeated freeze/thaw cycles.

Analysis Note


embryonic or early post-natal rat brain.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany


Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Storage Class

10 - Combustible liquids




Not applicable


Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Documents related to the products that you have purchased in the past have been gathered in the Document Library for your convenience.

Visit the Document Library

Difficulty Finding Your Product Or Lot/Batch Number?

Product numbers are combined with Pack Sizes/Quantity when displayed on the website (example: T1503-25G). Please make sure you enter ONLY the product number in the Product Number field (example: T1503).


Product Number
Pack Size/Quantity

Additional examples:





enter as 1.000309185)

Having trouble? Feel free to contact Technical Service for assistance.

Lot and Batch Numbers can be found on a product's label following the words 'Lot' or 'Batch'.

Aldrich Products

  • For a lot number such as TO09019TO, enter it as 09019TO (without the first two letters 'TO').

  • For a lot number with a filling-code such as 05427ES-021, enter it as 05427ES (without the filling-code '-021').

  • For a lot number with a filling-code such as STBB0728K9, enter it as STBB0728 without the filling-code 'K9'.

Not Finding What You Are Looking For?

In some cases, a COA may not be available online. If your search was unable to find the COA you can request one.

Request COA

Bala T S Susarla et al.
Journal of neurochemistry, 119(4), 868-878 (2011-09-08)
Traumatic injury to the CNS results in increased expression and deposition of chondroitin sulfate proteoglycans (CSPGs) that are inhibitory to axonal regeneration. Transforming growth factor-β (TGF-β) has been implicated as a major mediator of these changes, but the mechanisms through
Frauke Seehusen et al.
PloS one, 11(7), e0159752-e0159752 (2016-07-22)
In demyelinating diseases, changes in the quality and quantity of the extracellular matrix (ECM) may contribute to demyelination and failure of myelin repair and axonal sprouting, especially in chronic lesions. To characterize changes in the ECM in canine distemper demyelinating
Wu-Fu Chen et al.
CNS neuroscience & therapeutics, 21(9), 698-707 (2015-07-21)
To date, no reliable methods have proven effective for treating spinal cord injury (SCI). Even systemic administration of methylprednisolone (MP) remains controversial. We previously reported that intrathecal (i.t.) administration of granulocyte colony-stimulating factor (G-CSF) improves outcome after experimental spinal cord
José Javier Miguel-Hidalgo et al.
Scientific reports, 13(1), 16419-16419 (2023-09-30)
Major depressive disorder (MDD) and chronic unpredictable stress (CUS) in animals feature comparable cellular and molecular disturbances that involve neurons and glial cells in gray and white matter (WM) in prefrontal brain areas. These same areas demonstrate disturbed connectivity with
Verena Haist et al.
Brain pathology (Zurich, Switzerland), 22(2), 188-204 (2011-07-20)
The accumulation of extracellular matrix (ECM) and glial scar formation are considered important factors for the failure of regeneration in central nervous system (CNS) injury and multiple sclerosis. Theiler's murine encephalomyelitis (TME) as a model of multiple sclerosis served to

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service